2005.07.08 1
1978 1993 2 6 10 5 10 4 5, 2
CAI., / 1981 1989 1996 2000 2003 3
30 NIH - Cancer Research, Cancer Cell, Journal of Clinical Investigation 1 7 1987 1991 1995 Depogen IV ABI 20 1999-2000 SER Effects of levetiracetam on absence-like seizures and tonic convulsion in spontaneously epileptic rats 4
2 1970 (55 ) 1980 1982 1987 1988, β 1982 1992 1985 -NO, 30 57 3 5
SCI CABA 6 5 1 15 9 1 2 3. 4 5 3 4 1990-1991 20 1986 1987 1988 1992 4,, 1993 2000 6
1990 2002 2002-1994 2003 2003-2004 1998 2004.05~2005.05 1999 2002 2003. 09~2004. 08 2004 2000 2003 2000 2003 2000 2003 2004 7
2002 2003-2004 2004 2001 2004 2004 2005 13 62% 5 1 9 4 5194 35 10 35-50 5 50 6 50 15 71.4% 70% 8
21 20001 9 99 4 4 9
99 4 1234 4 5811 14, 42% 68 40 a. 2 2 10
b. 13 13 7 3 24 85 11
3 15% 15% 70% 45% 100% 99 85 40 8 86 86 7 99 t- 4 117 4 117 70 3 (p<0.01, p<0.05) 12
( ) PBL 2 0.5 0.5 0.5 1989 1992 1995 1997 2003 2003 / 198852 7-9 1988242 1990 1992 1992 3 54-55 1993 3 40-41 1994 1 13
16-17 1994 1 28-29 1995 1 77 91 32-33 1995 1 46-48 1997 1997 1997142 96 58 1997; 4(6) 3-4 199851 3 199933-4 1999; 3 5-6 2002 1 19-20 2002 2 57-58 961997.5 2003.5 ( ) 85 ( ) 86 ( ) 86 ( ) 14
178 100 68 32 8 7 2 15
spontaneously epileptic ratser 100% 70% 30% 40% 50% 16
,,, 90 3 21 100% 9 300 / 10 12 17
, 2001 Human PharmacologyMosby 1995 Pharmacology Lippincott s Illustrated Reviews 2nd Edition 2003 2003 2004 2001 ( ) ftp//202.118.43.131 18
2000 // 1987 1987 1989 1989 1992 1994 1998 2002 1995 1995 1996 1997 1998 1998 1998 1999 2001 2001 2002 2002 ( ) 2002 2004 ( ) ( ) 2004 19
Fundamental medical 2004 pharmacology 2004 2005 2005 RM6240C 722 YSD4G DJW1 Magnus,,,,,,,, 7 2005 1999 20
2000 ATP 2000 2001 2002 2002 2002 5-FU 2003 Pharmacological therapy of obesity Gene mutation and gene therapy of 2003 epilepsy 2003 Nitric oxide in teating lung disease 2004 2004 2004 2005 2005 2005 2005 2005 2005 β 2005 2005 2005 2005 2005 2000 21
2001 CGRP 2000 β 2002 2002 2004 2005 α 2005 1993 5 ~1993 6 1994 4 ~1994 8 1994 11 ~1995 5 1994 11 ~1995 5 1995 5 ~1995 12 1995 9 1995 11 ~1996 4 1996 12 ~1997 5 L- 22
1996 11 ~1997 12 2002 7 ~2002 12 2002 9 ~2002 12 2002 11 ~2003 5 2002 10 ~2003 5 2004 4 ~2004 12 2004 5 ~2004 11 2004 8 ~ 2004 9 ~ CAI 50%; 70%; 100%; 100%; 100% 23
CAI Pharmacology.,,,. 68 40 PBL 7 24
3 15% 15% 70% 45% 1 1 2 M 1 3 1 4 DNA 1 5 - - 1 6 GABA 1 7 1 8 1 9 1 25
10 1 11 1 12 1 CAI 1 2 3 4 5 6 5000 powerpoint powerpoint powerpoint powerpoint 7 96., ( ), ( ),,, 90 26
95,,,, -,, ; -, ; -, ; - ;, ; ; 27
,, 11,,,,, 12,, 1999,, 1998 2002 2001-2002,, 2004,, 2004 2004,, 2004,, 2004 2005 1985 1990 Ca 2+ K + 28
CGRP 80 HPLC OK432 5-FU - 90 M RyR 29
M 1. Mechanisms of BRCA1 Dysfunction in Human Breast Cancer, supported by Breast Cancer Research Foundation of United States (Tracs ID 27266, co-principle investigator) 2. Genetics of Breast Cancer in Blacks, supported by National Institutes of Health/National Cancer Institute of United States (RO1, CA89085-01A1 co-principle investigator) 3., 2001.01-2003.12 (No.30070849,); 19.00 4., 1997.01-1999.12 (No.39600178); 9.00 5. RyR 1998.01-1999.1296-1-205; 5.20 6. M, 1993.01-1995.12 (No.39270774); 5.00 7. Propofol 1997.10-1999.12; 2.00 1. 2002.3-19.0, 21997.7-1999.12 4.0 32001.3-2003.3 2.0 42003-2006 6.0 52001.6-2003.7 21 B13034 0.5 6 2002-13-01-002 1. α 237 1985.1~1988.12, 6.5 2., 39270309, 1993.1~1995.12, 3.5 3. A39970349, 2000.1~2002.12, 11.0 30
4. -NO 962321, 1997.1~2001.1, 3.0 5. (1035 ) COPD QF-8 1996.10~1999.12 96-901-045.0 6., 1995.04~1998.04. 1 NaCa 39070930 1991.11993.12 3.5 2. 397707581998.1-2000.12. 9.0 3... 0.5. 1996.10-1998.12.. 4. 39400138 1995.11997.12 7.0 5. 39870338 10 1998.1-2002.12. 2. 6. E 1 619370. 2.0. 1998.1-1999.12. 2. 7 3027053519.0 2003.12005.12. 8 ATP 2002 2020120114.0 2002.92005.8 1. 2. 3. 4. OK432 5-FU 31